查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2012514

疼痛管理治療市場：2026-2032年全球市場預測（依藥物類別、給藥途徑、適應症、通路和最終用戶分類）

Pain Management Therapeutics Market by Drug Class, Route Of Administration, Indication, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，疼痛管理治療市場價值將達到 900.7 億美元，到 2026 年將成長至 937.8 億美元，到 2032 年將達到 1267.5 億美元，複合年成長率為 5.00%。

主要市場統計數據
基準年 2025 900.7億美元
預計年份：2026年 937.8億美元
預測年份 2032 1267.5億美元
複合年成長率 (%) 5.00%

快速變化的臨床、監管和商業環境正在重塑疼痛管理的格局，需要以證據為基礎、與相關人員一致的策略。

在臨床創新、監管改革和相關人員期望變化的推動下，疼痛管理領域正迅速發展並呈現出多元化的趨勢。藥理學的進步、對鴉片類藥物管理的日益重視以及非藥物療法的加速發展，正在拓展臨床醫生可選擇的治療方案。因此，治療模式正從單一的治療方法轉向更個人化和多元化的方法，優先考慮療效、安全性和功能性結果。

多元化的臨床實踐、數位療法和強大的供應鏈正在融合，重塑治療模式，加速實施進程。

近年來，醫療保健領域發生了一系列變革性變化，重新定義了疼痛管理、治療和評估的方法。臨床上，人們對多方面鎮痛的認知不斷加深，將藥物療法和非藥物療法相結合，以改善治療效果並減少鴉片類藥物的使用。這項轉變的促進因素包括：關於過度依賴鴉片類藥物的長期危害的新證據，以及保險公司鼓勵患者堅持使用替代療法和治療方案的政策。

關稅驅動的供應鏈重組、近岸外包措施以及支付方的成本擔憂，已經重塑了整個產業的營運重點和策略投資。

2025年關稅及相關貿易措施的實施，為整個疼痛管理產業的相關人員帶來了一系列新的營運和策略考量。對於依賴全球化供應鏈的製造商而言，關稅帶來的成本增加促使他們重新評估採購決策、原料替代品和製造地地點。在許多情況下，企業採取的應對措施包括增加庫存緩衝、將關鍵零件的採購轉移到成本更低的國家，或投資近岸外包以降低關稅波動帶來的風險。

多方面的細分框架整合了藥物類別、給藥途徑、適應症、分銷管道和最終用戶特徵，以確定目標機會。

要了解疼痛管理領域中臨床機會與商業性需求的交會點，需要採用細緻的細分觀點。按藥物類別分類，該領域涵蓋輔助鎮痛藥、局部麻醉劑、非類固醇消炎劑(NSAIDs) 和鴉片類藥物。神經性疼痛藥物又可細分為抗驚厥藥和抗憂鬱症； 非類固醇又可細分為 COX-2 抑制劑和傳統 NSAIDs；鴉片類藥物則可細分為強效鴉片類藥物和弱效鴉片類藥物。每種藥物類別的細分市場都展現出獨特的療效、安全性和監管特徵，進而影響處方標準和報銷考量。

支付方結構、監管多樣性和醫療保健服務模式的區域差異，在美洲、歐洲、中東、非洲和亞太地區形成了不同的商業性路徑。

區域趨勢對疼痛管理療法的產品策略、監管管道和商業化方式有顯著影響。在美洲，鴉片類藥物管理政策的率先實施、術前術後護理中多模態治療方案的廣泛應用，以及私人保險公司對保險覆蓋範圍和報銷決策持續的重大影響，共同營造了一種環境，在這種環境下，可證實的實際療效和經濟價值更能引起消費者的共鳴。

這是一個既合作又競爭的市場環境，成熟的製藥公司、專業的創新者、醫療設備合作夥伴和數位領域的新參與企業齊聚一堂，共同創造綜合治療解決方案。

疼痛管理領域的競爭動態呈現出多元化的特點，既有老牌製藥公司，也有專業研發企業、醫療設備製造商和數位醫療領域的新興參與企業，它們各自為市場帶來不同的優勢。老牌製藥公司憑藉其廣泛的商業化網路、與支付方和醫療服務提供者建立的穩固關係以及深厚的臨床試驗經驗，在市場中佔據一席之地，但它們也面臨著突破傳統鴉片類藥物產品組合的創新壓力。

採取切實可行的策略，加強證據產生、供應鏈韌性、整合產品設計和個人化市場進入，以確保永續的競爭優勢。

引領當前疼痛管理市場發展的產業領導者應採取以實證醫學主導、相關人員為中心的策略，使臨床開發與商業性需求保持一致。優先創建可操作的真實世界證據和以患者為中心的結果，以證明功能改善和後續資源利用減少，從而滿足臨床醫生和支付方的需求。根據對醫療保健系統至關重要的終點指標客製化研究設計，以加速處方集採納和臨床應用。

採用嚴謹的混合方法研究途徑，結合專家訪談、文獻整合和三角測量分析，以檢驗策略見解和意義。

本報告整合了混合研究框架的洞見，該框架結合了第一手和第二手研究，以確保結果的穩健性和三角檢驗。第一手資料包括對臨床意見領袖、支付方、醫院採購經理和商業部門領導者的結構化訪談，以及諮詢小組檢驗關鍵主題趨勢的討論。這些定性數據輔以對同行評審文獻、監管指南、臨床試驗註冊數據、技術白皮書和公共聲明的廣泛審查，以建立最新的依證。

以證據為基礎的差異化、適應性經營模式和協作創新為重點的結論性、綜合性分析，確保了長期採用和價值實現。

總而言之，疼痛管理療法的市場格局正處於轉折點，其特點是臨床創新、監管力度加大以及對價值的日益重視。多模態治療的轉變、利用數位科技和醫療設備的輔助性治療的興起，以及對具有韌性的供應鏈的需求，都為產品開發商和服務供應商創造了一個更複雜但也充滿機會的環境。成功的關鍵在於能否產生有意義的真實世界數據，為不同的支付者建立引人注目的價值提案，並部署能夠反映當地醫療服務實際情況的高度適應性商業模式。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 疼痛管理治療市場：依藥物類別分類

  • 輔助止痛藥
  • 局部麻醉劑
  • 神經性疼痛藥物
    • 抗驚厥藥物
    • 抗憂鬱症
  • 非類固醇消炎劑
    • COX-2抑制劑
    • 傳統非類固醇抗發炎藥
  • 鴉片類藥物
    • 強效鴉片類藥物
    • 弱鴉片類藥物

第9章 疼痛管理治療市場：依給藥途徑分類

  • 口服
  • 腸外
    • 肌肉內部
    • 靜脈
    • 皮下
  • 外用
  • 經皮

第10章 疼痛管理治療市場：依適應症分類

  • 急性疼痛
  • 慢性疼痛
    • 腰痛
    • 神經性慢性疼痛
    • 骨關節炎
    • 類風濕性關節炎
  • 發炎性疼痛
  • 神經性疼痛

第11章 疼痛管理治療市場：依通路分類

  • 離線
  • 線上

第12章 疼痛管理治療市場：依最終使用者分類

  • 門診手術中心
  • 居家照護設施
    • 安寧療護
    • 病人家
  • 醫院
    • 私立醫院
    • 公立醫院

第13章 疼痛管理治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 疼痛管理治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 疼痛管理治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國疼痛管理治療市場

第17章：中國疼痛管理治療市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • AbbVie Inc.
  • AstraZeneca plc
  • Bayer AG
  • Boston Scientific Corporation
  • Eli Lilly and Company
  • Endo International plc
  • GlaxoSmithKline plc
  • Grunenthal GmbH
  • Johnson & Johnson
  • Mallinckrodt plc
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Purdue Pharma LP
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Vertex Pharmaceuticals Incorporated
  • Viatris Inc.
Product Code: MRR-431388EE3C5C

The Pain Management Therapeutics Market was valued at USD 90.07 billion in 2025 and is projected to grow to USD 93.78 billion in 2026, with a CAGR of 5.00%, reaching USD 126.75 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 90.07 billion
Estimated Year [2026] USD 93.78 billion
Forecast Year [2032] USD 126.75 billion
CAGR (%) 5.00%

A rapidly evolving clinical, regulatory, and commercial environment reshapes pain therapeutics and requires evidence-driven, stakeholder-aligned strategies

The pain management therapeutics landscape is undergoing a rapid, multi-dimensional evolution driven by clinical innovation, regulatory recalibration, and shifting stakeholder expectations. Advances in pharmacology, greater emphasis on opioid stewardship, and the acceleration of nonpharmacologic adjuncts have collectively broadened the therapeutic toolkit available to clinicians. As a result, treatment paradigms are moving away from one-size-fits-all regimens toward more individualized, multimodal approaches that prioritize efficacy, safety, and functional outcomes.

Simultaneously, payer and provider frameworks are increasingly focused on value-based care, outcome measurement, and cost containment. This environment compels product developers and service providers to substantiate not only clinical benefits but also real-world effectiveness and economic value. Regulatory bodies are responding with enhanced oversight of opioid prescribing, tighter controls around certain adjuvant therapies, and clearer guidance on clinical endpoints.

From a commercial perspective, market access strategies must now accommodate a more fragmented set of stakeholders, including integrated delivery networks, ambulatory surgery centers, home care providers, and digital health platforms. In this context, companies that align clinical evidence generation with pragmatic deployment models and stakeholder-specific value propositions will be best positioned to influence care pathways and gain durable adoption.

Multimodal clinical practices, digital therapeutics, and resilient supply chains converge to reshape treatment paradigms and accelerate adoption pathways

Recent years have seen several transformative shifts that are redefining how pain is treated, measured, and managed across care settings. Clinically, there is growing acceptance of multimodal analgesia that combines pharmacologic and nonpharmacologic modalities to improve outcomes while reducing opioid exposure. This shift is reinforced by emerging evidence on the long-term harms of opioid overreliance and by payer policies that incentivize alternatives and pathway adherence.

Technological innovation is also altering the landscape. Digital therapeutics, remote monitoring, wearable sensors, and telehealth-enabled pain management programs are enabling continuous assessment of patient-reported outcomes and facilitating more responsive titration of therapies. In parallel, advances in drug delivery, including long-acting injectables and transdermal systems, are expanding options for sustained analgesia with improved adherence profiles.

Supply chain and manufacturing resilience have become strategic priorities after global disruptions highlighted vulnerabilities in sourcing and production. Companies are therefore reassessing geographic footprints, diversifying supplier bases, and investing in onshore capabilities to mitigate future shocks. This realignment is occurring alongside a shift in clinical trial design that emphasizes pragmatic endpoints, decentralized enrollment, and patient-centric measures, which together accelerate evidence generation and adoption in real-world practice.

Tariff-induced supply chain recalibration, nearshoring initiatives, and payer cost-concerns reshaped operational priorities and strategic investments across the industry

The imposition of tariffs and related trade measures in 2025 introduced a new set of operational and strategic considerations for stakeholders across the pain therapeutics continuum. For manufacturers that rely on globalized supply chains, tariff-related cost increases have prompted granular re-evaluations of sourcing decisions, input substitution, and manufacturing footprints. In many cases, companies responded by increasing inventory buffers, shifting critical components to alternative, lower-cost sourcing countries, or investing in nearshoring initiatives to reduce exposure to tariff volatility.

These operational adjustments have had secondary effects on product development timelines and commercial strategies. Firms prioritized investments that offered resilience or differentiated value, such as advanced delivery systems or device-drug combinations less vulnerable to commodity price swings. Contract negotiations with distributors and payers now routinely include tariff mitigation clauses and pass-through mechanics, which has influenced pricing discussions and reimbursement negotiations.

At the clinical level, the tariff environment reinforced the importance of cost-effective therapeutic options and accelerated payer interest in therapies that deliver demonstrable reductions in utilization of high-cost services. As a result, companies that can evidence total cost of care benefits or that offer integrated service models gained negotiating leverage. Overall, the tariff context has elevated operational agility and supply chain transparency into core competitive capabilities for industry participants.

A multi-dimensional segmentation framework integrates drug classes, delivery modes, indications, distribution channels, and end-user contexts to reveal targeted opportunities

A nuanced segmentation lens is essential for understanding where clinical opportunity and commercial traction intersect in the pain therapeutics space. Based on drug class, the field spans adjuvant analgesics, local anesthetics, neuropathic pain agents, nonsteroidal anti-inflammatory drugs, and opioids, with the neuropathic pain agents further divided into anticonvulsants and antidepressants, the nonsteroidal category bifurcated into Cox-2 inhibitors and traditional NSAIDs, and the opioid class separated into strong and weak opioids. Each drug-class subsegment exhibits distinct efficacy, safety, and regulatory profiles that shape prescriber preference and reimbursement considerations.

Based on route of administration, therapeutic delivery channels include oral, parenteral, topical, and transdermal options, while the parenteral route itself is differentiated across intramuscular, intravenous, and subcutaneous modalities. Delivery format influences adherence, onset of action, and suitability for ambulatory versus inpatient settings, and it informs the design of clinical trials and real-world evidence programs.

Based on indication, the therapeutic landscape covers acute pain, cancer pain, chronic pain, inflammatory pain, and neuropathic pain, with chronic pain further dissected into low back pain, neuropathic chronic pain, osteoarthritis, and rheumatoid arthritis. Indication-specific outcomes, patient-reported measures, and comorbidity profiles dictate both clinical development priorities and commercialization tactics.

Based on distribution channel, products reach patients through offline and online pathways, with digital pharmacies and telehealth-enabled dispensing changing access dynamics. Finally, based on end user, the marketplace serves ambulatory surgical centers, home care settings, and hospitals, with home care settings subdivided into hospice care and patient home, and hospitals separated into private and public institutions. These end-user distinctions determine procurement cycles, formulary decisions, and required supporting services, and they influence the optimal commercial model for launch and scale.

Regional payer structures, regulatory diversity, and care delivery models create distinct commercial pathways across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics exert a powerful influence on product strategy, regulatory pathways, and commercialization approaches within pain management therapeutics. The Americas continue to exhibit advanced adoption of opioid stewardship policies, widespread integration of multimodal perioperative programs, and significant private payer influence on coverage and reimbursement decisions, creating an environment where demonstrable real-world outcomes and economic value resonate strongly with purchasers.

In Europe, Middle East & Africa, regulatory heterogeneity and diverse payer architectures require adaptable market access strategies and local evidence generation to support formulary inclusion. Reimbursement rules in several jurisdictions emphasize conservative use of high-cost interventions and favor established nonpharmacologic care pathways, prompting companies to design localized value dossiers and to pursue partnerships with regional health systems.

Across Asia-Pacific, rapid uptake of innovative delivery platforms, expanding ambulatory care infrastructure, and growing investment in home-based services are fostering new channels for distribution and patient engagement. The region also presents opportunities to leverage manufacturing scale and cost efficiencies, though companies must navigate varied regulatory timelines and local clinical practice patterns. Together, these regional contours demand differentiated go-to-market blueprints that align clinical evidence, pricing strategies, and stakeholder engagement to regional payer and provider realities.

A collaborative competitive landscape where pharmaceutical incumbents, specialty innovators, device partners, and digital entrants converge to create integrated therapeutic solutions

Competitive dynamics in the pain therapeutics domain are defined by a mix of legacy pharmaceutical players, specialty developers, device manufacturers, and digital health entrants, each bringing different strengths to market. Incumbent pharmaceutical companies leverage broad commercialization networks, established relationships with payers and providers, and deep clinical trial expertise, but they face pressure to innovate beyond traditional opioid-centric portfolios.

Specialized innovators focus on novel mechanisms of action, advanced delivery systems, and combination product strategies that seek to differentiate on efficacy, safety, or convenience. These firms often pursue strategic alliances with device makers or digital health firms to create integrated solutions that support adherence and remote monitoring. Device manufacturers are increasingly partnering with pharmaceutical developers to co-develop drug-device combinations that extend patent life and improve therapeutic precision.

Digital health companies are introducing behavioral therapies, remote monitoring, and AI-enabled pain-tracking tools that complement pharmacologic regimens and provide meaningful patient-reported outcome data. Collaboration, rather than pure competition, is emerging as a sustainable model; alliances between large manufacturers and agile disruptors enable acceleration of time-to-market while de-risking innovation. Overall, companies that combine robust clinical evidence, differentiated delivery, and clear value propositions for payers and providers are most likely to sustain commercial momentum.

Actionable strategies to strengthen evidence generation, supply chain resilience, integrated product design, and tailored market access for sustained competitive advantage

Industry leaders seeking to navigate the current pain therapeutics environment should pursue evidence-led, stakeholder-centric strategies that align clinical development with commercial imperatives. First, prioritize generation of pragmatic real-world evidence and patient-centered outcomes that demonstrate functional improvement and reductions in downstream resource utilization, thereby meeting the dual needs of clinicians and payers. Align study designs with the endpoints that matter to health systems to accelerate formulary acceptance and clinical adoption.

Second, diversify supply chains and consider onshoring or regional manufacturing to reduce exposure to tariff and trade volatility while ensuring consistent product availability. Transparency in supplier relationships and proactive inventory management will strengthen contracting positions with large health systems. Third, invest in hybrid product models that pair pharmacologic therapies with digital tools or device components to improve adherence, enable remote titration, and produce richer longitudinal data for value demonstration.

Fourth, tailor market access approaches to regional payer architectures and care delivery models, building localized value dossiers and forming partnerships with provider networks for pilot deployments. Finally, cultivate cross-sector collaborations and licensing arrangements to share development risk and accelerate commercialization capacity, focusing on segments where differentiated clinical benefits and durable reimbursement pathways are plausible.

A rigorous mixed-methods research approach combining expert interviews, literature synthesis, and triangulated analyses to validate strategic insights and implications

This report synthesizes insights derived from a mixed-methods research framework combining primary and secondary approaches to ensure robust, triangulated findings. Primary inputs include structured interviews with clinical thought leaders, payers, hospital procurement executives, and commercial leaders, as well as advisory panel discussions that validated key thematic trends. These qualitative inputs were complemented by an extensive review of peer-reviewed literature, regulatory guidance, clinical trial registries, technology white papers, and public policy statements to construct an up-to-date evidence base.

Analytical methods included thematic coding of expert interviews to identify recurring strategic priorities, scenario mapping to explore potential operational responses to tariff shifts, and comparative analysis across delivery formats and indications to surface niche opportunities. The segmentation framework was validated through cross-referencing procurement practices and formulary policies across hospital, ambulatory, and home care settings. Limitations of the methodology include the evolving nature of regulatory guidance and the variability of regional reimbursement rules, which were addressed by including time-bound caveats and by recommending continuous surveillance for policy changes.

Throughout, data integrity was prioritized via source triangulation and expert validation to ensure that conclusions reflect a balanced and pragmatic view of the industry landscape.

Conclusive synthesis emphasizing evidence-driven differentiation, adaptive commercial models, and collaborative innovation to secure long-term adoption and value realization

In summary, the pain management therapeutics landscape is at an inflection point characterized by clinical innovation, heightened regulatory scrutiny, and a stronger emphasis on value. The shift toward multimodal care, the rise of digital and device-enabled adjuncts, and the need for resilient supply chains have together created a more complex but opportunity-rich environment for product developers and service providers. Success will depend on the ability to generate meaningful real-world evidence, to craft compelling value propositions for diverse payers, and to deploy adaptive commercial models that reflect regional care delivery realities.

Companies that embrace collaborative development models, prioritize patient-centric outcomes, and invest in operational flexibility will be better positioned to capture opportunity and mitigate risk. The implications extend across the product lifecycle, from clinical development and regulatory strategy to manufacturing and post-market support. Ultimately, the landscape rewards organizations that can translate clinical differentiation into demonstrable improvements in patient function and health system performance, thereby securing sustainable adoption and long-term relevance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Pain Management Therapeutics Market, by Drug Class

  • 8.1. Adjuvant Analgesics
  • 8.2. Local Anesthetics
  • 8.3. Neuropathic Pain Agents
    • 8.3.1. Anticonvulsants
    • 8.3.2. Antidepressants
  • 8.4. Nonsteroidal Anti-Inflammatory Drugs
    • 8.4.1. Cox-2 Inhibitors
    • 8.4.2. Traditional NsaiDs
  • 8.5. Opioids
    • 8.5.1. Strong Opioids
    • 8.5.2. Weak Opioids

9. Pain Management Therapeutics Market, by Route Of Administration

  • 9.1. Oral
  • 9.2. Parenteral
    • 9.2.1. Intramuscular
    • 9.2.2. Intravenous
    • 9.2.3. Subcutaneous
  • 9.3. Topical
  • 9.4. Transdermal

10. Pain Management Therapeutics Market, by Indication

  • 10.1. Acute Pain
  • 10.2. Chronic Pain
    • 10.2.1. Low Back Pain
    • 10.2.2. Neuropathic Chronic Pain
    • 10.2.3. Osteoarthritis
    • 10.2.4. Rheumatoid Arthritis
  • 10.3. Inflammatory Pain
  • 10.4. Neuropathic Pain

11. Pain Management Therapeutics Market, by Distribution Channel

  • 11.1. Offline
  • 11.2. Online

12. Pain Management Therapeutics Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Home Care Settings
    • 12.2.1. Hospice Care
    • 12.2.2. Patient Home
  • 12.3. Hospitals
    • 12.3.1. Private Hospitals
    • 12.3.2. Public Hospitals

13. Pain Management Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Pain Management Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Pain Management Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Pain Management Therapeutics Market

17. China Pain Management Therapeutics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. AbbVie Inc.
  • 18.7. AstraZeneca plc
  • 18.8. Bayer AG
  • 18.9. Boston Scientific Corporation
  • 18.10. Eli Lilly and Company
  • 18.11. Endo International plc
  • 18.12. GlaxoSmithKline plc
  • 18.13. Grunenthal GmbH
  • 18.14. Johnson & Johnson
  • 18.15. Mallinckrodt plc
  • 18.16. Merck & Co., Inc.
  • 18.17. Novartis AG
  • 18.18. Pfizer Inc.
  • 18.19. Purdue Pharma L.P.
  • 18.20. Sanofi S.A.
  • 18.21. Sun Pharmaceutical Industries Ltd.
  • 18.22. Teva Pharmaceutical Industries Ltd.
  • 18.23. Vertex Pharmaceuticals Incorporated
  • 18.24. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ADJUVANT ANALGESICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ADJUVANT ANALGESICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ADJUVANT ANALGESICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COX-2 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COX-2 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COX-2 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRADITIONAL NSAIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRADITIONAL NSAIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRADITIONAL NSAIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY STRONG OPIOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY STRONG OPIOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY STRONG OPIOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY WEAK OPIOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY WEAK OPIOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY WEAK OPIOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ACUTE PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ACUTE PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ACUTE PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOW BACK PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOW BACK PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOW BACK PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC CHRONIC PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC CHRONIC PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC CHRONIC PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OSTEOARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OSTEOARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INFLAMMATORY PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INFLAMMATORY PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INFLAMMATORY PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPICE CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPICE CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPICE CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PATIENT HOME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PATIENT HOME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PATIENT HOME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 224. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 238. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 239. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 240. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2032 (USD MILLION)
  • TABLE 241. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 242. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 243. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 244. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 245. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 246. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 247. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 248. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 250. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 277. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 278. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 279. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2032 (USD MILLION)
  • TABLE 280. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 281. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 282. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 283. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 284. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 285. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 286. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 287. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 288. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 289. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 290. NATO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 291. NATO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 292. NATO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2032 (USD MILLION)
  • TABLE 293. NATO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 294. NATO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 295. NATO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 296. NATO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 297. NATO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 298. NATO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 299. NATO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 300. NATO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 301. NATO